Literature DB >> 30610740

High-dose corticosteroids for acute cytomegalovirus-associated transverse myelitis in the immunocompetent patient: a case report and systematic review.

A Budhram1, Y Liu2, M Krawczyk3, T L H Chan3, J G Burneo3, S M Hosseini-Moghaddam4, C Shoesmith3.   

Abstract

We present an immunocompetent patient with transverse myelitis (TM) during acute cytomegalovirus (CMV) infection, as evidenced by a reactive serum CMV IgM and CMV viremia. The patient had an excellent outcome after receiving only high-dose methylprednisolone. Given concerns that practitioners may have around the use of immunosuppressive therapy for this potentially infectious myelopathy, we systematically reviewed the literature to assess outcomes after administration of high-dose corticosteroids to this population. Despite severe disease at clinical nadir with inability to ambulate, immunocompetent patients with acute CMV-associated TM who received high-dose corticosteroids had good clinical outcomes 1 month to 1 year after presentation.

Entities:  

Keywords:  Corticosteroids; Cytomegalovirus; Immunocompetent; Methylprednisolone; Myelitis

Year:  2019        PMID: 30610740     DOI: 10.1007/s13365-018-0717-2

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  14 in total

1.  Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  T F Scott; E M Frohman; J De Seze; G S Gronseth; B G Weinshenker
Journal:  Neurology       Date:  2011-12-07       Impact factor: 9.910

Review 2.  Cytomegalovirus-associated transverse myelitis: a review of nine well-documented cases.

Authors:  Ferhat Arslan; Mesut Yilmaz; Yahya Paksoy; Ergenekon Karagöz; Ali Mert
Journal:  Infect Dis (Lond)       Date:  2014-11-12

3.  Acute myeloradiculitis due to cytomegalovirus as the initial manifestation of AIDS.

Authors:  F Mahieux; F Gray; G Fenelon; R Gherardi; D Adams; A Guillard; J Poirier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

4.  Is methyl prednisolone useful in acute transverse myelitis?

Authors:  J Kalita; U K Misra
Journal:  Spinal Cord       Date:  2001-09       Impact factor: 2.772

5.  Factors influencing PCR detection of viruses in cerebrospinal fluid of patients with suspected CNS infections.

Authors:  N W S Davies; L J Brown; J Gonde; D Irish; R O Robinson; A V Swan; J Banatvala; R S Howard; M K Sharief; P Muir
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

6.  Idiopathic acute transverse myelitis: application of the recent diagnostic criteria.

Authors:  J de Seze; C Lanctin; C Lebrun; I Malikova; C Papeix; S Wiertlewski; J Pelletier; O Gout; C Clerc; C Moreau; G Defer; G Edan; F Dubas; P Vermersch
Journal:  Neurology       Date:  2005-12-27       Impact factor: 9.910

7.  Cytomegalovirus-associated transverse myelitis in a non-immunocompromised patient.

Authors:  D Karacostas; C Christodoulou; A Drevelengas; M Paschalidou; P Ioannides; A Constantinou; I Milonas
Journal:  Spinal Cord       Date:  2002-03       Impact factor: 2.772

Review 8.  Proposed diagnostic criteria and nosology of acute transverse myelitis.

Authors: 
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

Review 9.  Cytomegalovirus-associated acute transverse myelitis in immunocompetent adults.

Authors:  C A Fux; S Pfister; F Nohl; S Zimmerli
Journal:  Clin Microbiol Infect       Date:  2003-12       Impact factor: 8.067

10.  Cytomegalovirus associated transverse myelitis in an immunocompetent host with DNA detection in cerebrospinal fluid; a case report.

Authors:  Suneth Karunarathne; Dumitha Govindapala; Yapa Udayakumara; Harshini Fernando
Journal:  BMC Res Notes       Date:  2012-07-20
View more
  1 in total

1.  Extensive longitudinal myelitis due to cytomegalovirus infection.

Authors:  Rihab Ben Dhia; Mouna Aissi; Mariem Mhiri; Mahbouba Frih Ayed
Journal:  J Neurovirol       Date:  2021-08-27       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.